Amundi lowered its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 98.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,988 shares of the company's stock after selling 98,904 shares during the quarter. Amundi's holdings in 10x Genomics were worth $31,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in TXG. Blue Trust Inc. grew its position in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after buying an additional 1,299 shares in the last quarter. Sound Income Strategies LLC increased its stake in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after acquiring an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in 10x Genomics during the fourth quarter worth approximately $52,000. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 53.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock valued at $66,000 after purchasing an additional 1,012 shares in the last quarter. Finally, SRS Capital Advisors Inc. increased its position in shares of 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after purchasing an additional 4,324 shares during the period. Institutional investors own 84.68% of the company's stock.
10x Genomics Stock Performance
Shares of NASDAQ TXG traded down $0.17 during mid-day trading on Wednesday, reaching $9.58. The company had a trading volume of 3,843,030 shares, compared to its average volume of 2,022,134. 10x Genomics, Inc. has a twelve month low of $9.27 and a twelve month high of $38.49. The stock's 50 day moving average is $12.46 and its 200-day moving average is $15.30. The stock has a market capitalization of $1.17 billion, a PE ratio of -6.30 and a beta of 1.93.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, sell-side analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on TXG. Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Barclays cut their target price on shares of 10x Genomics from $19.00 to $18.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Canaccord Genuity Group dropped their price target on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Citigroup decreased their target price on 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $20.21.
Check Out Our Latest Stock Analysis on TXG
Insiders Place Their Bets
In related news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. This trade represents a 1.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 5,092 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.
10x Genomics Company Profile
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
